Chlorotrianisene
 |
|
| Clinical data | |
|---|---|
| Trade names | Tace |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy category |
|
| Routes of administration |
Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 50 to 80% |
| Identifiers | |
|
|
| Synonyms | NSC-10108 |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| ECHA InfoCard | 100.008.472 |
| Chemical and physical data | |
| Formula | C23H21ClO3 |
| Molar mass | 380.864 g/mol |
| 3D model (Jmol) | |
|
|
|
|
  (what is this?)
|
|
Chlorotrianisene (INN, USAN, BAN; brand names Tace, Estregur, Anisene, Clorotrisin, Merbentyl, Triagen, many others; also known as CTA; tri-p-anisylchloroethylene, TACE, or tris(p-methoxyphenyl)chloroethylene) is a synthetic, non-steroidal estrogen of the triphenylethylene group that was formerly used for the treatment of menopausal symptoms, estrogen deficiency, and prostate cancer before being discontinued. It was approved in the United States as TACE in 1952, and was introduced throughout Europe subsequently. CTA was the first estrogenic compound of the triphenylethylene series to be introduced.
CTA was derived from estrobin (DBE), a derivative of the very weakly estrogenic compound triphenylethylene (TPE), which in turn was derived from structural modification of diethylstilbestrol (DES). CTA is a relatively weak estrogen, with about one-eighth the potency of DES. However, it is highly lipophilic and is stored in fat tissue for prolonged periods of time, with its slow release from fat resulting in a very long duration of action. CTA itself is inactive; it behaves as a prodrug to a weak estrogen that is formed as a metabolite via degradation of CTA in the liver. As such, the potency of CTA is reduced if it is given parenterally instead of orally.
...
Wikipedia